CanSino Biologics Celebrates the Rollout of the Inhaled Vaccine, Convidecia Air™, in Shanghai
share
Excerpt
Cansino Biologics announced that the Joint Prevention and Control Mechanism of the State Council of China had approved its Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation (trade name: Convidecia AirTM) for inclusion in Shanghai’s booster vaccination programme. This marks the beginning of the rollout of the world’s first inhaled COVID-19 vaccine, Convidecia AirTM.
Article Summary
Cansino Biologics announced that the Joint Prevention and Control Mechanism of the State Council of China had approved its Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation (trade name: Convidecia AirTM) for inclusion in Shanghai’s booster vaccination programme. This marks the beginning of the rollout of the world’s first inhaled COVID-19 vaccine, Convidecia AirTM.
Adults who have received two doses of inactivated vaccines or one dose of Convidecia after a six-month interval and are 18 years of age or older may choose to get one dose of Convidecia Air as a booster without charge.
Clinical trial applications for Convidicia AirTM were authorised in March 2021. The National Medical Products Administration of China (“NMPA”) gave the vaccine the Emergency Use Authorization in 2022 for use as a booster dose. ConvideciaTM, the intramuscular version of CanSinoBIO’s COVID-19 vaccine, was granted conditional marketing authorisation in China in February 2021 and entered the country’s heterologous immunisation programme in February 2022 as the first and only adenovirus-vectored vaccine.
Convidecia Air has demonstrated to be an innovative solution that offers safe and effective protection for people through a needle-free, painless, and non-invasive delivery method without any serious adverse events observed[1]. It is based on the adenovirus vector technological platform of the intramuscular version developed by CanSinoBIO and the proprietary vibrating mesh aerosol drug delivery technology developed by Aerogen.
Comments
Leave A Comment
Leave a Reply
